Bioactive Compounds and Diabetes Mellitus: Prospects and Future Challenges

Author:

Rahman Md. Mominur1,Islam Md. Rezaul1,Rabbi Fazle1,Islam Mohammad Touhidul1,Sultana Sharifa1,Ahmed Muniruddin1,Sehgal Aayush2,Singh Sukhbir2,Sharma Neelam2,Behl Tapan2ORCID

Affiliation:

1. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh

2. Chitkara College of Pharmacy, Chitkara University, Punjab, India

Abstract

Abstract: Diabetes mellitus is a metabolic condition that influences the endocrine framework. Hyperglycemia and hyperlipidemia are two of the most widely recognized metabolic irregularities in diabetes and two of the most well-known reasons for diabetic intricacies. Diabetes mellitus is a persistent illness brought about by metabolic irregularities in hyperglycemic pancreatic cells. Hyperglycemia can be brought about by an absence of insulin-producing beta cells in the pancreas (Type 1 diabetes mellitus) or inadequate insulin creation that does not work effectively (Type 2 diabetes mellitus). Present diabetes medication directs blood glucose levels in the systemic circulation to the typical levels. Numerous advanced prescription medicines have many negative results that can bring about unexpected severe issues during treatment of the bioactive compound from a different source that is beneficially affected by controlling and adjusting metabolic pathways or cycles. Moreover, a few new bioactive medications disengaged from plants have shown antidiabetic action with more noteworthy adequacy than the oral hypoglycemic agent that specialists have utilized in clinical treatment lately. Since bioactive mixtures are collected from familiar sources, they have a great activity in controlling diabetes mellitus. This study discusses bioactive compounds, their activity in managing diabetes mellitus, and their prospects. Though bioactive compounds have many health-beneficial properties, adequate clinical studies still need to acknowledge that they effectively manage diabetes mellitus.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference202 articles.

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications : Report of a WHO consultation Part 1, Diagnosis and classification of diabetes mellitus 1999. World Health Organization 1999. Available from:

2. Heise T.; Nosek L.; Rønn B.B.; Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004,53(6),1614-1620

3. McIntyre H.D.; Catalano P.; Zhang C.; Desoye G.; Mathiesen E.R.; Damm P.; Gestational diabetes mellitus. Nat Rev Dis Primers 2019,5(1),47

4. Faselis C.; Katsimardou A.; Imprialos K.; Deligkaris P.; Kallistratos M.; Dimitriadis K.; Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol 2020,18(2),117-124

5. Type 1 Diabetes information on MedicineNet.com. MedicineNet 2021. Available from:

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3